This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 222.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 337.50% and 235.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 7.14% and 34.43%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 232.56% and 332.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 162.16% and 374.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
3 Top Cancer Biotechs to Keep An Eye On in 2025
by Kinjel Shah
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
by Nalak Das
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 35.56% and 103.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice
by Zacks Equity Research
Does Monte Rosa Therapeutics (GLUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 14% and 46.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
by Zacks Equity Research
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 107.8% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal fourth-quarter sales.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter.
Lantheus (LNTH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) third-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)
by Zacks Equity Research
Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%
by Zacks Equity Research
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.